Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: Early-Onset Familial AD: News
News
eFAD News Search  
Research Brief: Auguste D.'s Mutation Identified?
20 May 2010. Writing the latest pages of an anthropological mystery, scientists propose in this month’s Archives of Neurology that it is highly possible that Auguste Deter, the first identified Alzheimer disease patient, carried the N141I presenilin-2 mutation—the same one as in present-day U.S. families descended from German emigrants who settled near the river Volga in Russia. Based on new molecular genetic data, Thomas Bird, University of Washington, Seattle, and colleagues suggest that Volga German descendents and a present-day German family living in Deter’s home state, Hesse, share this PS2 mutation, as well as a chunk of chromosome 1 surrounding it. “This means it is extremely likely they have a common ancestor,” Bird told ARF. “We think there is interesting circumstantial evidence—historical, social, geographic, and genetic—that Alzheimer's original patient might also have had this mutation."

More than 20 years ago, Bird’s lab came across a handful of German-American families with early-onset AD and several shared surnames. The scientists went on to find 11 such families and trace them all to a single ethnic group, the Volga Germans, who lived in or near present-day Frankfurt, in Hesse. Lured by the Russian Empress Catherine the Great’s offers of land—and assurance that they could keep their German heritage and avoid the Russian draft—the families migrated in the late 1770s to Russia’s Volga River region. They lived there in relative social and genetic isolation. When the going got tough, some came to the U.S. between 1880 and 1920 seeking cheap land and opportunities that came with the construction of transcontinental railroads in the Great Plains. Their descendents eventually came to the attention of Bird and colleagues, who speculated that these families’ AD came from an autosomal dominant gene inherited from a single ancestor (Bird et al., 1988). “We thought they probably represented a genetic founder effect,” Bird said.

Their hunch was correct. All 11 families had the same mutation in PS2 (Levy-Lahad et al., 1995), the early-onset AD gene with the fewest identified pathogenic mutations to date. (See Jayadev et al., 2010 for a comprehensive analysis of AD phenotypes and genotypes linked to PS2 mutations.) Knowing that Auguste D., Alois Alzheimer’s original patient, lived in the Frankfurt area and developed early-onset AD around age 50, just like the Volga German families, Bird and colleagues wondered whether she could have had the same PS2 mutation. “It’s perfectly conceivable that this woman was an ancestor of some of the Volga German families who stayed behind in Germany,” Bird said. “But we didn’t have any evidence for that.”

Since then, a few developments bolstered their fledgling hypothesis. The first came in 1995 when a team of curious doctors found—fully intact in a University of Munich basement—a photo of Alzheimer’s first AD patient, his original notes on her, and the brain tissue taken at autopsy. Analyzing DNA from tissue on her histopathological slides, researchers showed that Auguste D. did not have the ApoE4 late-onset AD risk allele (in fact, she was homozygous for ApoE3), and that her APP gene had no known AD mutations (Graeber et al., 1997; Graeber et al., 1998). They had begun screening for presenilin mutations but, due to limited tissue availability, postponed the analyses until the field had a deeper understanding of AD genetic defects.

While the ApoE and APP findings were consistent with the idea that Auguste D. had the N141I PS2 mutation, a key piece of evidence had yet to emerge. “If our hypothesis was true,” Bird said, “somebody with the mutation ought to appear in modern-day Germany.”

In 2008, scientists reported for the first time a family living in Hesse with early-onset AD caused by the N141I PS2 mutation (Nikisch et al., 2008). “We thought this was one of the missing links,” Bird told ARF. “A case has popped up in modern-day Germany that says there are people left in Germany who have this mutation.” Bird took this as additional evidence that Alzheimer's original case was one of those left-behind individuals.

To establish further evidence, first author Chang-En Yu and colleagues did a haplotype analysis on a DNA sample from the proband of the present-day German early-onset AD (EOAD) family. They compared it to DNA from 130 people from existing Volga German pedigrees, and showed that chromosomal markers flanking the N141I mutation were the same for all subjects. “Not only do they have the same mutation,” Bird said, “but there’s strong evidence they have the same piece of chromosome 1.” This suggests the same gene region has segregated in the current Hesse family as in those Volga German families over the years, he said. That Auguste D. lived in the same Hesse region and had AD with similar onset age (47 years vs. 55.5 years for American Volga German families) further suggested that she might be the connection between the modern-day Hesse family and the U.S. Volga Germans.

The largest Volga German AD pedigree to date comes from the family of Gary Reiswig, a retired city planner and educator in East Hampton, New York. Reiswig was 25 when he learned that his father had early-onset AD, as did 10 of his 13 paternal aunts and uncles. Now 70, Reiswig chronicles his family’s experience with the disease in his recently published book, The Thousand Mile Stare (see ARF related news story). Reiswig shares end-of-life anecdotes of several afflicted family members that bear a resemblance to descriptions of Auguste D. in the final stage of her disease.

“While this does not add any scientific evidence, I think these observations could be more than interesting coincidences,” Reiswig noted in an e-mail to ARF. He also remarked on a striking familial resemblance between Auguste D. and his own family (see full comment below).

However, definitive evidence that Auguste D. had the PS2 N141I mutation has yet to come. “The potential to prove it and document it is there,” said Bird, referring to targeted mutation analysis of brain tissue from Auguste D.’s autopsy slides. He said the scientists in Germany who control access to those specimens have thus far been “extraordinarily cautious.”

In the meantime, some researchers are happy merely to have an early-onset AD family to analyze, noting that such families have been exceedingly hard to find in Germany.—Esther Landhuis.

Reference:
Yu CE, Marchani E, Nikisch G, Müller U, Nolte D, Hertel A, Wijsman EM, Bird TD. The N141I mutation in PSEN2: implications for the quintessential case of Alzheimer disease. Arch Neurol. 2010 May;67(5):631-3. Abstract

 
Comments on News and Primary Papers
  Comment by:  Gary Reiswig
Submitted 20 May 2010  |  Permalink Posted 20 May 2010

In The Thousand Mile Stare, I describe a frightening scene in which my sister threatened to kill my brother-in-law because she thought he was a stranger who broke into the house. This is only one of a number of incidents in which paranoid behavior has been exhibited by members of my family while in the throes of living with Alzheimer's. I also described how one of my uncles, who was institutionalized as was Frau D., lay curled up in the fetal position, incontinent and unresponsive in the final stage of his disease. This also happened to more than one of my family members. These descriptions are quite similar to Dr. Alzheimer's observations of his patient, who did not trust, and was at times, afraid of her family, and reacted in a paranoid fashion to her caregivers. And, she was described in the final stage of her disease as lying in her bed, curled in the fetal position, incontinent and unresponsive. I find the similarity of the descriptions of Frau D.'s suffering uncannily similar to the suffering of my family, and the age of onset of her symptoms and death are precisely...  Read more

  Primary Papers: The N141I mutation in PSEN2: implications for the quintessential case of Alzheimer disease.

Comment by:  Johannes Streffer
Submitted 21 May 2010  |  Permalink Posted 21 May 2010

The discussion of founder effects of the different FAD mutations is an interesting topic and can increase our knowledge about familial Alzheimer disease, maybe even AD overall.

This mutation is certainly very old. It is possible that it traveled from Germany to the Volga region and then the U.S. One question one could ask next is whether the phenotype of the disease caused by a given mutation expressed in different environments is different. To do this, it would be necessary to compare phenotypes in larger pedigrees living in separated, well-defined areas.

Having a family described in Fulda is clear proof that this particular presenilin-2 mutation is still “alive” in Germany. More generally, there are surprisingly few FAD cases with demonstrated mutations in Germany, as compared to Sweden, England, Spain, and Belgium, for example. Whether this is due to relatively little ongoing human AD genetics research, few carriers, or few large pedigrees in Germany remains an open question. An argument toward the second possibility is that for other neurodegenerative diseases...  Read more


  Primary Papers: The N141I mutation in PSEN2: implications for the quintessential case of Alzheimer disease.

Comment by:  Gary Miner
Submitted 27 May 2010  |  Permalink Posted 27 May 2010
  I recommend this paper

This is certainly the evidence we all have been waiting for: a "Founder" effect originating in Germany, rather than the Volga River region of Russia where this mutation had been traced to previously. This discovery by Dr. Tom Bird and colleagues at the University of Washington-Seattle may unfold to show that the number of people affected by this mutated gene is larger than previously thought, e.g., that the families from Fulda, Germany, and the American Volga German families with eFAD share the same N141I PSEN2 mutation on an identical haplotypic background. [Editor's note: Gary Miner is prominently featured in Gary Reiswig's book, The Thousand Mile Stare; see ARF related news story.]

References:
Familial Alzheimer's Disease: Molecular Genetics & Clinical Perspectives, Edited by Miner, Richter, Blass, Valentine, and Winters-Miner, 1989. Dekker, NY: ISBN 0-8247-8068-X (alk.paper)

View all comments by Gary Miner
Comments on Related Papers
  Related Paper: Alzheimer's disease phenotypes and genotypes associated with mutations in presenilin 2.

Comment by:  Andre Delacourte
Submitted 22 April 2010  |  Permalink Posted 28 April 2010
  I recommend this paper
Comments on Related News
  Related News: Research Brief: Auguste D. Did Not Have Volga German Mutation

Comment by:  Jean-François Foncin
Submitted 24 September 2011  |  Permalink Posted 24 September 2011

Was the first step of any genetic investigation, namely the study of the family history of the proband, undertaken in the case of Auguste D. beyond the succinct notes in her clinical record? Her father died aged 45 (no diagnosis given), her mother aged 64 of pneumonia, her three brothers are "healthy" (their ages not given) and "there is no mental illness in the family." Given the high "a priori" probability of dominant inheritance in instances of what is now called early-onset Alzheimer's disease (EOAD), the age at death of both her parents is within two standard deviations for affected EOAD family members (1). Incidentally, we found "pneumonia" as the registered cause of death for a number of EOAD patients in our Calabrian study. There is a 0.8 probability for at least one of her brothers and 0.5 for her daughter to have been a carrier, and a non-negligible one for contemporary descendants to be affected.

A family reconstruction along the lines of what we did for family N (FAD1), which later came to be the index for the PS1 M146L mutation, would certainly be feasible, and...  Read more

  Submit a Comment on this News Article
Cast your vote and/or make a comment on this news article. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Country or Territory:
*Login Email Address  
*Password    Minimum of 8 characters
*Confirm Password  
Stay signed in?  

I recommend the Primary Papers

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


*Enter the verification code you see in the picture below:


This helps Alzforum prevent automated registrations.

Terms and Conditions of Use:Printable Version

By clicking on the 'I accept' below, you are agreeing to the Terms and Conditions of Use above.
Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark
Not Seeing Eye to Eye: Do Lenses Accumulate Aβ?
Gammagard™ Misses Endpoints in Phase 3 Trial
Guidelines at Nature Aim to Stem Tide of Irreproducibility
Paper Alert: Antisense Oligonucleotide Therapy Safe for ALS?
New Assays for Aβ Oligomers in CSF Claim Femtogram Sensitivity
Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad